InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

BioAtla, Inc.

BCAB Clue Score36
United States Fiscal year ends December CIK 0001826892
$1.25 -16.67% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.25 −95.28% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 16 Dec 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−28.3Net income−29.9Fiscal year 2020Operating income−30.1Net income−35.9Fiscal year 2021Revenue0.3Operating income−96.4Net income−95.4EPS, diluted−2.76Fiscal year 2022Operating income−108.1Net income−106.5EPS, diluted−2.74Fiscal year 2023Operating income−129.7Net income−123.5EPS, diluted−2.58Fiscal year 2024Operating income−73.9Net income−69.8EPS, diluted−1.44Fiscal year 2025Operating income−59.3Net income−59.6EPS, diluted−1.01
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 0.3 n/a n/a n/a n/a
Growth
Operating income −28.3 −30.1 −96.4 −108.1 −129.7 −73.9 −59.3
Net income −29.9 −35.9 −95.4 −106.5 −123.5 −69.8 −59.6
Growth
EPS, diluted n/a n/a −2.76 −2.74 −2.58 −1.44 −1.01
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2020Fiscal year 2021Operating margin−32,146.7%Net margin−31,800.7%Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a −32,146.7% n/a n/a n/a n/a
Net margin n/a n/a −31,800.7% n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2019Operating cash flow−9.6Fiscal year 2020Operating cash flow−36.3Fiscal year 2021Operating cash flow−62.2Fiscal year 2022Operating cash flow−90.4Fiscal year 2023Operating cash flow−104.0Fiscal year 2024Operating cash flow−71.9Fiscal year 2025Operating cash flow−48.2
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −9.6 −36.3 −62.2 −90.4 −104.0 −71.9 −48.2

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2019Cash3.7Shareholders’ equity−56.0Fiscal year 2020Cash238.6Shareholders’ equity210.0Fiscal year 2021Cash245.0Shareholders’ equity210.8Fiscal year 2022Cash215.5Shareholders’ equity180.3Fiscal year 2023Cash111.5Shareholders’ equity70.7Fiscal year 2024Cash49.0Shareholders’ equity14.3Fiscal year 2025Cash7.1Shareholders’ equity−36.2
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 3.7 238.6 245.0 215.5 111.5 49.0 7.1
Shareholders’ equity −56.0 210.0 210.8 180.3 70.7 14.3 −36.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
n/a n/a −32,146.7% n/a n/a n/a n/a
n/a n/a −31,800.7% n/a n/a n/a n/a
Spending
n/a n/a 19,424.7% n/a n/a n/a n/a
n/a n/a 12,805.3% n/a n/a n/a n/a
Returns
n/a −17.1% −45.3% −59.0% −174.7% −489.1% n/a
n/a −14.6% −37.5% −47.2% −103.2% −133.1% −431.1%
Balance and payout
n/a 14.3% 17.1% 20.1% 40.9% 72.8% 361.7%